blonanserin has been researched along with Schizophrenia in 50 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (6.00) | 29.6817 |
| 2010's | 26 (52.00) | 24.3611 |
| 2020's | 21 (42.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujita, K; Iga, JI; Inada, K; Ishigooka, J; Iwata, N; Kanda, Y; Kikuchi, Y; Kishi, T; Kishimoto, T; Koretsune, S; Nakagome, K; Ohi, K; Ohmori, T; Sekiyama, K; Shichijo, T; Tabuse, H; Terada, H; Tsutsumi, Y | 1 |
| Hashimoto, N; Ishikawa, S; Ito, YM; Kusumi, I; Okubo, R; Sato, N; Sawagashira, R; Yamamura, R | 1 |
| Kuramitsu, A; Ohi, K; Shioiri, T; Sugiyama, S; Takai, K | 1 |
| Nakamura, T; Sasayama, D; Takahashi, K; Washizuka, S; Yokotsuka-Ishida, S | 1 |
| Hu, Y; Wen, H; Zheng, Y | 1 |
| Iwata, N; Kishi, T; Matsuura, A; Nakamura, H | 1 |
| Bo, Q; Deng, H; Hu, S; Inoue, Y; Lei, L; Liu, Z; Pu, C; Sheng, J; Wang, L; Wu, B; Yang, F; Yu, X | 1 |
| Hagikura, M; Inada, T | 1 |
| Bo, Q; Cai, D; Chen, J; Deng, H; Li, H; Li, J; Li, K; Liu, X; Sang, H; Sun, M; Wang, G; Wang, X; Xun, Z; Yang, X; Zhan, G; Zhang, R; Zhao, G | 1 |
| Deng, SW; Hong, B; Jiang, WL; Li, BH; Sun, DW; Xu, Q; Yang, HB | 1 |
| Agarkov, A; Correll, CU; Cosca, R; Higuchi, T; Inoue, Y; Ishigooka, J; Iwata, N; Kane, JM; Kim, WH; Lin, SK; Matsui, T; Sato, T; Suchkov, Y; Sulaiman, AH; Wang, L; Watabe, K; Yoon, BH | 1 |
| Andrade, C; Harshe, D; Tekkalaki, B; Tharayil, HM | 1 |
| Harvey, PD; Miura, S; Nakamura, H | 1 |
| Lei, L; Li, H; Li, Y; Shen, Y; Yu, W; Yu, Y | 1 |
| Higuchi, T; Ishigooka, J; Iwata, N; Kanamori, Y; Matsumoto, M; Nakamura, H; Naoi, I | 1 |
| Iwata, N; Kishi, T; Matsuda, Y; Sakuma, K; Yoshimura, R | 1 |
| Begni, V; Brivio, P; Calabrese, F; Guidi, A; Marchisella, F; Molteni, R; Paladini, MS; Riva, MA; Spero, V | 1 |
| Endo, M; Fujita, K; Fukami, G; Hashimoto, T; Hata, T; Hattori, N; Hosoda, Y; Imamura, Y; Inoue, M; Ishikawa, M; Iyo, M; Kanahara, N; Kawasaki, Y; Kimura, A; Murakami, T; Niitsu, T; Nishimoto, M; Oda, Y; Ogawa, K; Sato, T; Seki, R; Shiina, A; Suzuki, M; Takase, N; Yoshida, T | 1 |
| Kakuyama, H; Kim, W; Nishibe, H; Okubo, Y; Sakayori, T; Tateno, A; Yamamoto, M | 1 |
| Akiyama, Y; Arihara, M; Kimura, Y; Komatsu, K; Mikami, T; Mikuni, N; Sakashita, K | 1 |
| Inoue, Y; Nakamura, H; Tsuchimori, K | 1 |
| Li, L; Liao, M; Liu, B; Xu, S; Zhang, Y; Zheng, Q | 1 |
| Hashimoto, N; Kuksumi, I; Miyamoto, T; Miyazaki, A; Toyomaki, A | 1 |
| Hagi, K; Hori, H; Iwata, N; Katsuki, A; Kishi, T; Matsuda, Y; Matsui, Y; Morita, K; Sanada, K; Shoji, Y; Yanagimoto, H; Yoshimura, R | 1 |
| Harvey, PD; Murasaki, M; Nakamura, H | 1 |
| Arakawa, R; Fukuta, H; Honjo, K; Ishihara, K; Kumita, S; Nakamura, H; Okubo, Y; Okumura, M; Tateno, A | 1 |
| Amrutheshwar, R; Dkhar, SA; George, M; Kattimani, S; Rajkumar, RP | 1 |
| Miyamoto, S; Tenjin, T | 1 |
| Suzuki, M; Takahashi, S; Uchiyama, M | 1 |
| Hasegawa, T; Hibi, S; Kito, S; Koga, Y; Mochida, M; Nakajima, T; Tobe, Y | 1 |
| Iwata, N; Kishi, T; Matsuda, Y | 2 |
| Kanno-Nozaki, K; Katsumi, A; Mashiko, H; Miura, I; Niwa, S; Shiga, T; Yabe, H | 1 |
| Miki, T; Mizuki, Y; Takaki, M | 1 |
| Kaneda, Y; Miyake, N; Miyamoto, S; Ninomiya, Y; Ogino, S; Sumiyoshi, T; Tenjin, T; Yamaguchi, N | 1 |
| Mizuki, Y; Takaki, M | 1 |
| Gu, N; Li, H; Li, J; Li, K; Li, L; Liu, C; Luo, X; Qi, S; Shi, J; Wang, C; Wang, L; Wang, Q; Yang, F; Yao, C; Zhang, H | 1 |
| Gopalakrishna, G; Ithman, MH; Lauriello, J | 1 |
| Hashimoto, T; Ishikawa, M; Iyo, M; Kanahara, N; Niitsu, T; Tachibana, M; Watanabe, M | 1 |
| Ishibashi, T; Nakamura, H; Nishikawa, H; Une, T | 1 |
| Garcia, E; Nakamura, H; Peris, F; Robert, M; Sato, N; Terazawa, Y | 1 |
| Deeks, ED; Keating, GM | 1 |
| Ishitobi, M; Kosaka, H; Murata, T; Shukunami, K; Wada, Y | 1 |
| Bahk, WM; Cho, HS; Jeon, YW; Jon, DI; Jung, HY; Kim, CH; Kim, HC; Kim, SH; Kim, YH; Kim, YK; Kwon, JS; Lee, SH; Lee, SY; Yang, J; Yi, JS; Yoon, BH | 1 |
| Kurotaki, N; Nishihara, K; Nobata, H; Nonaka, S; Ozawa, H | 1 |
| Anai, K; Arai, J; Funamoto, Y; Ito, Y; Kaneda, Y; Kitajima, R; Miyake, N; Miyamoto, S; Ogino, S; Ojima, K; Sumiyoshi, T; Tadokoro, M; Tenjin, T; Teramoto, H; Tsukahara, S; Yamaguchi, N | 1 |
| Gen, K; Suzuki, H | 1 |
| Fukui, N; Ono, S; Saito, M; Someya, T; Sugai, T; Suzuki, Y; Tsuneyama, N; Watanabe, J | 1 |
| Iwata, N; Kishi, T; Matsuda, Y; Nakamura, H | 1 |
| Furukawa, H; Furukawa, K; Kan, QM; Nabeshima, T; Nagai, T; Noda, Y; Une, T | 1 |
12 review(s) available for blonanserin and Schizophrenia
| Article | Year |
|---|---|
Efficacy and safety of blonanserin versus risperidone in the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antipsychotic Agents; Humans; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia | 2023 |
Blonanserin patch vs. Other Antipsychotics for Acute Schizophrenia: A Systematic Review of Double-blind, Randomized, Placebo-controlled, Phase 3 Trials in Japan.
Topics: Acute Disease; Administration, Cutaneous; Antipsychotic Agents; Clinical Trials, Phase III as Topic; Double-Blind Method; Humans; Japan; Piperazines; Piperidines; Randomized Controlled Trials as Topic; Schizophrenia | 2020 |
Safety and effectiveness of oral blonanserin for schizophrenia: A review of Japanese post-marketing surveillances.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Child; Female; Humans; Japan; Male; Middle Aged; Piperazines; Piperidines; Product Surveillance, Postmarketing; Safety; Schizophrenia; Treatment Outcome; Young Adult | 2021 |
[Research progress in mechanisms and clinical application for blonanserin and lurasidone in improving cognitive function of schizophrenia].
Topics: Antipsychotic Agents; Cognition Disorders; Humans; Lurasidone Hydrochloride; Piperazines; Piperidines; Schizophrenia; Schizophrenic Psychology | 2017 |
Efficacy, Tolerability, and Safety of Blonanserin in Schizophrenia: An Updated and Extended Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Antipsychotic Agents; Humans; Piperazines; Piperidines; Randomized Controlled Trials as Topic; Schizophrenia | 2019 |
Newer antipsychotics and upcoming molecules for schizophrenia.
Topics: Antipsychotic Agents; Dibenzocycloheptenes; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Isoindoles; Isoxazoles; Lurasidone Hydrochloride; Piperazines; Piperidines; Schizophrenia; Thiazoles | 2013 |
[Blonanserin in the treatment of schizophrenia].
Topics: Antipsychotic Agents; Cognition; Humans; Japan; Piperazines; Piperidines; Quality of Life; Schizophrenia; Treatment Outcome | 2013 |
Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Double-Blind Method; Glycated Hemoglobin; Heart; Humans; Isoindoles; Piperazines; Piperidines; Randomized Controlled Trials as Topic; Risk; Schizophrenia; Thiazoles; Weight Gain | 2014 |
Update on New and Emerging Treatments for Schizophrenia.
Topics: Antipsychotic Agents; Drug Approval; Excitatory Amino Acid Agents; Glycine Agents; Humans; Minocycline; Nicotinic Agonists; Phosphodiesterase Inhibitors; Piperazines; Piperidines; Schizophrenia | 2016 |
[Pharmacological profiles and clinical effects of blonanserin (Lonasen) on schizophrenia].
Topics: Animals; Antidepressive Agents, Second-Generation; Cognition Disorders; Dopamine D2 Receptor Antagonists; Double-Blind Method; Drug Discovery; Drug-Related Side Effects and Adverse Reactions; Humans; Piperazines; Piperidines; Randomized Controlled Trials as Topic; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome | 2008 |
Blonanserin: a review of its use in the management of schizophrenia.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Drug Interactions; Humans; Piperazines; Piperidines; Schizophrenia; Schizophrenic Psychology | 2010 |
Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials.
Topics: Antiparkinson Agents; Double-Blind Method; Humans; Piperazines; Piperidines; Psychiatric Status Rating Scales; PubMed; Randomized Controlled Trials as Topic; Schizophrenia; Treatment Outcome | 2013 |
16 trial(s) available for blonanserin and Schizophrenia
| Article | Year |
|---|---|
Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second-generation antipsychotics: 52-week evaluation of JUMPs, a randomized, open-label study.
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Japan; Male; Medication Adherence; Middle Aged; Paliperidone Palmitate; Piperazines; Piperidines; Remission Induction; Schizophrenia; Social Interaction; Treatment Outcome | 2022 |
Switching from blonanserin oral tablets/powders to transdermal patches alleviates extrapyramidal symptoms in patients with schizophrenia: A 52-week open-label study.
Topics: Administration, Oral; Adult; Antiparkinson Agents; Antipsychotic Agents; Dose-Response Relationship, Drug; Dyskinesias; Female; Humans; Male; Piperazines; Piperidines; Powders; Schizophrenia; Tablets; Transdermal Patch | 2022 |
Effectiveness and safety of blonanserin for improving social and cognitive functions in patients with first-episode schizophrenia: a study protocol for a prospective, multicentre, single-arm clinical trial.
Topics: Antipsychotic Agents; Cognition; Humans; Multicenter Studies as Topic; Piperazines; Piperidines; Prospective Studies; Schizophrenia; Schizophrenic Psychology; Social Interaction; Treatment Outcome | 2022 |
Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Piperidines; Psychiatric Status Rating Scales; Schizophrenia; Transdermal Patch | 2020 |
Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8-week, multicenter, double-blind, randomized controlled study.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Humans; Japan; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Piperidines; Risperidone; Schizophrenia | 2020 |
Model-based analysis of therapeutic efficacy of blonanserin and risperidone in schizophrenia patients and effects on prolactin: A randomized double-blind study.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Models, Statistical; Piperazines; Piperidines; Prolactin; Risperidone; Schizophrenia; Sex Factors; Young Adult | 2020 |
Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study.
Topics: Administration, Cutaneous; Adult; Aged, 80 and over; Asian People; Female; Humans; Male; Middle Aged; Piperazines; Piperidines; Schizophrenia; Transdermal Patch; Treatment Outcome | 2020 |
A randomized-controlled trial of blonanserin and olanzapine as adjunct to antipsychotics in the treatment of patients with schizophrenia and dopamine supersensitivity psychosis: The ROADS study.
Topics: Antipsychotic Agents; Benzodiazepines; Dopamine; Humans; Olanzapine; Piperazines; Piperidines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Treatment Outcome | 2020 |
Striatal Dopamine D2 Receptor Occupancy Induced by Daily Application of Blonanserin Transdermal Patches: Phase II Study in Japanese Patients With Schizophrenia.
Topics: Adult; Antipsychotic Agents; Corpus Striatum; Female; Humans; Japan; Male; Middle Aged; Piperazines; Piperidines; Positron-Emission Tomography; Raclopride; Receptors, Dopamine D2; Schizophrenia; Transdermal Patch; Young Adult | 2021 |
Blonanserin versus haloperidol in Japanese patients with schizophrenia: A phase 3, 8-week, double-blind, multicenter, randomized controlled study.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Tolerance; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Piperidines; Schizophrenia; Weight Gain | 2019 |
One-year follow-up study of psychotic patients treated with blonanserin: a case series.
Topics: Adult; Antipsychotic Agents; Female; Follow-Up Studies; Humans; Piperazines; Piperidines; Prolactin; Psychotic Disorders; Quality of Life; Schizophrenia | 2013 |
Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Chromatography, High Pressure Liquid; Female; Homovanillic Acid; Humans; Japan; Male; Methoxyhydroxyphenylglycol; Middle Aged; Piperazines; Piperidines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Time Factors; Treatment Outcome | 2014 |
Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Asian People; China; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Piperidines; Prolactin; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Weight Gain; Young Adult | 2015 |
The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Haloperidol; Humans; International Cooperation; Male; Middle Aged; Piperazines; Piperidines; Prospective Studies; Psychiatric Status Rating Scales; Schizophrenia; Severity of Illness Index; Young Adult | 2009 |
Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Piperazines; Piperidines; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Weight Gain; Young Adult | 2010 |
Effect of blonanserin on cognitive function in antipsychotic-naïve first-episode schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Chronic Disease; Cognition Disorders; Female; Humans; Male; Piperazines; Piperidines; Prospective Studies; Psychiatric Status Rating Scales; Quality of Life; Schizophrenia; Severity of Illness Index; Single-Blind Method; Treatment Outcome; Young Adult | 2012 |
22 other study(ies) available for blonanserin and Schizophrenia
| Article | Year |
|---|---|
The type rather than the daily dose or number of antipsychotics affects the incidence of hyperglycemic progression.
Topics: Adult; Antipsychotic Agents; Clozapine; Dibenzothiepins; Female; Haloperidol; Humans; Hyperglycemia; Incidence; Japan; Male; Middle Aged; Piperazines; Piperidines; Prospective Studies; Schizophrenia | 2022 |
Improved response to electroconvulsive therapy after switching from haloperidol to blonanserin in a patient with treatment-resistant schizophrenia.
Topics: Antipsychotic Agents; Electroconvulsive Therapy; Haloperidol; Humans; Piperazines; Piperidines; Schizophrenia; Schizophrenia, Treatment-Resistant | 2022 |
Case report of bradycardia induced by blonanserin in schizophrenia.
Topics: Antipsychotic Agents; Bradycardia; Humans; Piperazines; Piperidines; Schizophrenia | 2022 |
Early improvement as a predictor of response to blonanserin transdermal patch in patients with schizophrenia.
Topics: Antipsychotic Agents; Humans; Piperazines; Piperidines; Schizophrenia; Transdermal Patch | 2022 |
A case of schizophrenia with relapsed catatonia successfully treated with blonanserin transdermal patch.
Topics: Adult; Antipsychotic Agents; Catatonia; Female; Humans; Schizophrenia; Transdermal Patch | 2023 |
Effectiveness and safety of blonanserin in young and middle-aged female patients with schizophrenia: data from a post-marketing surveillance.
Topics: Antipsychotic Agents; Female; Humans; Middle Aged; Product Surveillance, Postmarketing; Prolactin; Prospective Studies; Schizophrenia; Treatment Outcome; Weight Gain | 2023 |
Blonanserin patch for schizophrenia.
Topics: Humans; Piperazines; Piperidines; Schizophrenia | 2020 |
Chronic treatment with the antipsychotic drug blonanserin modulates the responsiveness to acute stress with anatomical selectivity.
Topics: Animals; Antipsychotic Agents; Brain; Drug Administration Schedule; Genes, Immediate-Early; Male; Piperazines; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Schizophrenia; Stress, Psychological | 2020 |
COVID-19 infection in Hokkaido, Japan might depend on the viscosity of atmospheric air.
Topics: COVID-19; Double-Blind Method; Humans; Japan; Piperazines; Piperidines; SARS-CoV-2; Schizophrenia; Transdermal Patch; Viscosity | 2021 |
Olanzapine, blonanserin, and aripiprazole associated with different frontostriatal reward system activation in patients with schizophrenia.
Topics: Adult; Anticipation, Psychological; Antipsychotic Agents; Aripiprazole; Female; Humans; Magnetic Resonance Imaging; Male; Olanzapine; Piperazines; Piperidines; Prefrontal Cortex; Reward; Schizophrenia; Ventral Striatum | 2018 |
Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.
Topics: Adult; Antipsychotic Agents; Blood-Brain Barrier; Brain; Case-Control Studies; Corpus Striatum; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Piperazines; Piperidines; Positron-Emission Tomography; Pyrrolidines; Raclopride; Receptors, Dopamine D2; Salicylamides; Schizophrenia; Tissue Distribution; Young Adult | 2013 |
Successful treatment with blonanserin for drug-induced hyperprolactinemia in chronic schizophrenia patients: a six-month follow-up of two cases.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Female; Follow-Up Studies; Humans; Hyperprolactinemia; Male; Middle Aged; Piperazines; Piperidines; Prolactin; Schizophrenia | 2013 |
Blonanserin improved dystonia induced by risperidone or olanzapine in two patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dystonia; Female; Humans; Olanzapine; Piperazines; Piperidines; Risperidone; Schizophrenia; Young Adult | 2014 |
Long-term efficacy and safety of blonanserin in patients with first-episode schizophrenia: a 1-year open-label trial.
Topics: Adult; Antipsychotic Agents; Female; Follow-Up Studies; Humans; Male; Piperazines; Piperidines; Quality of Life; Schizophrenia; Time Factors; Treatment Outcome | 2014 |
The position of blonanserin as a treatment for schizophrenia.
Topics: Antipsychotic Agents; Double-Blind Method; Humans; Multicenter Studies as Topic; Piperazines; Piperidines; Randomized Controlled Trials as Topic; Schizophrenia | 2014 |
Blonanserin ameliorated the tendency toward QTc prolongation associated with risperidone in a patient with schizophrenia.
Topics: Adult; Antipsychotic Agents; Female; Humans; Long QT Syndrome; Piperazines; Piperidines; Risperidone; Schizophrenia | 2015 |
Effectiveness of blonanserin for patients with drug treatment-resistant schizophrenia and dopamine supersensitivity: A retrospective analysis.
Topics: Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Dopamine; Drug Resistance; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Piperidines; Psychiatric Status Rating Scales; Retrospective Studies; Schizophrenia | 2016 |
Adjunctive treatment with low-dosage aripiprazole for blonanserin-induced hyperprolactinemia in a female patient with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dopamine Antagonists; Female; Humans; Hyperprolactinemia; Piperazines; Piperidines; Quinolones; Schizophrenia | 2010 |
Three cases of schizophrenia showing improvement after switching to blonanserin.
Topics: Adult; Antipsychotic Agents; Delusions; Dopamine Antagonists; Hallucinations; Humans; Male; Piperazines; Piperidines; Schizophrenia; Serotonin Antagonists; Treatment Outcome | 2011 |
The relationship between the plasma concentration of blonanserin, and its plasma anti-serotonin 5-HT(2A) activity/anti-dopamine D₂ activity ratio and drug-induced extrapyramidal symptoms.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle Aged; Piperazines; Piperidines; Receptors, Dopamine D2; Receptors, Serotonin, 5-HT2; Schizophrenia | 2012 |
Quetiapine-induced insulin resistance after switching from blonanserin despite a loss in both bodyweight and waist circumference.
Topics: Antipsychotic Agents; Dibenzothiazepines; Female; Homeostasis; Humans; Insulin Resistance; Piperazines; Piperidines; Quetiapine Fumarate; Schizophrenia; Waist Circumference; Weight Loss; Young Adult | 2012 |
Effect of AD-5423 on animal models of schizophrenia: phencyclidine-induced behavioral changes in mice.
Topics: Animals; Disease Models, Animal; Immobilization; Male; Mice; Motor Activity; Phencyclidine; Piperazines; Piperidines; Schizophrenia | 2003 |